1. Home
  2. NAAS vs PDSB Comparison

NAAS vs PDSB Comparison

Compare NAAS & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NaaS Technology Inc.

NAAS

NaaS Technology Inc.

HOLD

Current Price

$3.35

Market Cap

41.7M

ML Signal

HOLD

Logo PDS Biotechnology Corporation

PDSB

PDS Biotechnology Corporation

HOLD

Current Price

$0.23

Market Cap

43.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAAS
PDSB
Founded
2019
2005
Country
China
United States
Employees
N/A
10
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.7M
43.4M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
NAAS
PDSB
Price
$3.35
$0.23
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
18.2K
1.9M
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.16
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.80
$0.22
52 Week High
$4.54
$1.55

Technical Indicators

Market Signals
Indicator
NAAS
PDSB
Relative Strength Index (RSI) 52.78 17.87
Support Level $3.26 N/A
Resistance Level $3.47 $0.76
Average True Range (ATR) 0.22 0.07
MACD 0.00 -0.05
Stochastic Oscillator 50.00 3.46

Price Performance

Historical Comparison
NAAS
PDSB

About NAAS NaaS Technology Inc.

Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

Share on Social Networks: